image credit- shutterstock
US-based startup Xellar Biosystems, a globally leading innovator in next-generation artificial intelligence (AI)- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, has entered into a multi-year strategic collaboration agreement with Woojung Bio Co., a Korea-listed biotechnology company with strong capabilities in translational research and life sciences services.
Through this collaboration, the two companies will work together to integrate their complementary technologies and expertise to advance innovative, human-relevant research solutions in the life sciences field. Xellar will contribute its AI-enabled organ-on-a-chip platform, computer vision–based analysis pipelines, and advanced data analytics capabilities, while Woojung Bio will bring its extensive experience in translational research, biological services, and applied life-science studies.
The collaboration will focus on joint project development, workflow and technology integration, and the co-development of differentiated preclinical research solutions. By combining Xellar's next-generation in vitro platforms with Woojung Bio established translational and preclinical capabilities, the partnership aims to enhance research efficiency, improve data quality and reproducibility, and strengthen predictive approaches across drug discovery, safety evaluation, and related life-science applications.
